INS and metabolic syndrome: These findings are consistent with earlier clinical studies, such as those by Stagi et al. [46], which showed that use of the product in obese children and adolescents with type 1 diabetes and MetS led to significant improvements in BMI, waist circumference (WC), glycaemic control, and insulin requirements after just three months of treatment.